An analysis of more than 4000 adolescents and young adults in the US found those who more recently used tobacco products reported more symptoms than other users.
Robust safety and efficacy data supports advancing AZR-MD-001 into Phase 3 clinical trials TEL AVIV, Israel (BUSINESS WIRE) Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple pre.